Background: Centralized care for patients with pancreatic cancer is associated with longer survival. We hypothesized that increased travel distance from home is associated with increased survival for pancreatic cancer patients.
Methods: The National Cancer Database user file for all pancreatic cancer patients was investigated from 2004 through 2015. Distance from the patients' zip code to the treating facility was determined. Survival was investigated using the Kaplan-Meier method. Cox hazard ratios (CoxHRs) were determined based on stage of disease, distance traveled for care, and clinical factors.
Results: 340 780 patients were identified. In the average age of 68 ± 12 years, 51% were male and 83% were Caucasian. For all stages of cancer, longer survival was associated with traveling farther ( < .001). The survival advantage was longer for Caucasians than African Americans (3.7 months vs. 2.6 months, < .001) Travel was associated with a 13% decrease in risk of death ( < .001). Even controlling for the pathologic stage, traveling farther was associated with decreased risk of death (CoxHR = .91, < .001).
Discussion: Traveling for care is associated with improved survival for pancreatic cancer patients. While a selection bias may exist, the fact that all stages of patients investigated benefited suggests that this is a real phenomenon.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/0003134820951484 | DOI Listing |
Front Med (Lausanne)
December 2024
Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China.
Bacterial liver abscesses commonly occur in patients with immune deficiencies such as diabetes, post-chemotherapy, or post-immunosuppressive therapy. The recommended treatment for liver abscesses exceeding 5 cm in a diameter is anti-infection therapy combined with percutaneous catheter drainage. Complications may include local spread to adjacent tissues or organs and thrombosis of the liver and portal veins.
View Article and Find Full Text PDFFront Immunol
December 2024
Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, China.
Pancreatic adenosquamous carcinoma (PASC) is a rare subtype of pancreatic cancer (PC), with no established consensus on the optimal treatment for postoperative liver metastasis recurrence. We report a case of a 48-year-old male patient who underwent radical surgery and was pathologically diagnosed with microsatellite instability-high (MSI-H) PASC. The patient experienced liver metastasis recurrence following single-agent gemcitabine adjuvant chemotherapy.
View Article and Find Full Text PDFCureus
November 2024
Internal Medicine, Mayo Hospital, Lahore, PAK.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a poor prognosis. This poor prognosis is largely attributed to a late-stage diagnosis. Recent advancements in metabolomics have emerged as a promising avenue for biomarker discovery in PDAC.
View Article and Find Full Text PDFBiol Direct
December 2024
Center of Hepatobiliary Pancreatic Disease, Xuzhou Central Hospital, Xuzhou, Jiangsu, 221009, China.
Background: Hepatocellular carcinoma (HCC) is the leading cause of cancer-related deaths worldwide, and the lack of effective biomarkers for early detection leads to poor therapeutic outcomes. Prostaglandin E Synthase 3 (PTGES3) is a putative prognostic marker in many solid tumors; however, its expression and biological functions in HCC have not been determined. The proteolysis-targeting chimera (PROTAC) is an established technology for targeted protein degradation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!